Estrogen‐dependent signaling is intimately associated with hormone‐dependent breast cancer subtypes, while ERα is regarded as one of the most important players in breast cancer progression, serving not only as a prognostic biomarker, but also as a predictor of responsiveness to endocrine therapies [2, 14]. This evidence concerns the gene ESR1 and breast carcinoma.